Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

PartnershipLNP7457LNP8701Positive

AI Analysis

Summary

Lupin Limited announced the spinout of two oncology programs (LNP7457 targeting PRMT5 and LNP8701 targeting SOS1) to Kaveri Therapeutics, with Kaveri planning to raise capital to fund global clinical studies for these candidates.

Outcome Details

Lupin spinning out two oncology programs to Kaveri Therapeutics; Kaveri aims to raise capital to fund global clinical studies

Importance:6/10

Sentiment:

0.30

oncologyspinoutpartnershipcapital raisePRMT5SOS1

Related Companies

$DFPH $GBCYD

Read the original article

Published by PR Newswire Pharma on July 21, 2026 5:01 AM

Read Original